Leprosy primary prevention: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Primary prevention== | ==Primary prevention== | ||
Considering the importance of early diagnosis and treatment of leprosy, in order to prevent lifetime damage in patients, primary prevention gains an extraordinary importance, particularly in areas of the world with higher incidence of the disease. | Considering the importance of early [[diagnosis]] and [[Therapy|treatment]] of leprosy, in order to prevent lifetime damage in patients, [[primary prevention]] gains an extraordinary importance, particularly in areas of the world with higher [[incidence]] of the disease. | ||
Unfortunately up to today, there is still no adequate tool for the early detection of leprosy. | Unfortunately up to today, there is still no adequate tool for the early detection of leprosy. Immunoprophylaxis studies in different population groups with the [[BCG vaccine]], alone or in combination with killed [[Mycobacterium leprae]] or [[atypical Mycobacteria]], have shown an [[efficacy]] of 28 to 60%. To the best of nowadays's knowledge, a good coverage of [[BCG vaccine]] is still a major contribution to reduce the impact of leprosy in the populations. | ||
Immunoprophylaxis studies in different population groups with the BCG vaccine, alone | |||
==References== | ==References== | ||
Revision as of 00:44, 5 July 2014
|
Leprosy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leprosy primary prevention On the Web |
|
American Roentgen Ray Society Images of Leprosy primary prevention |
|
Risk calculators and risk factors for Leprosy primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Primary prevention
Considering the importance of early diagnosis and treatment of leprosy, in order to prevent lifetime damage in patients, primary prevention gains an extraordinary importance, particularly in areas of the world with higher incidence of the disease. Unfortunately up to today, there is still no adequate tool for the early detection of leprosy. Immunoprophylaxis studies in different population groups with the BCG vaccine, alone or in combination with killed Mycobacterium leprae or atypical Mycobacteria, have shown an efficacy of 28 to 60%. To the best of nowadays's knowledge, a good coverage of BCG vaccine is still a major contribution to reduce the impact of leprosy in the populations.